Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase IIb trial of a controlled-release minicapsule formulation of ciclosporin (CyCol) for the treatment of ulcerative colitis

Next Previous
X
Search
Trial Profile

Pivotal phase IIb trial of a controlled-release minicapsule formulation of ciclosporin (CyCol) for the treatment of ulcerative colitis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 23 Oct 2019 Trial design, Pivotal phase IIb trial of a controlled-release minicapsule formulation of ciclosporin (CyCol) for the treatment of ulcerative colitis, released at the 27th United European Gastroenterology Week
    • 30 Jul 2018 According to a Sublimity Therapeutics media release, in May 2018, Sublimity announced a US$64 million financing to further the development of STI-0529 including this study. The financing was co-led by OrbiMed and Longitude Capital with participation from HBM Healthcare Investments.
    • 22 May 2018 According to a Sublimity Therapeutics media release, Sigmoid Pharma has changed its name to Sublimity Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top